H-ARG-ARG-ARG-ARG-ARG-ARG-ARG-ARG-ARG-OH manufacturers
|
| H-ARG-ARG-ARG-ARG-ARG-ARG-ARG-ARG-ARG-OH Basic information |
| H-ARG-ARG-ARG-ARG-ARG-ARG-ARG-ARG-ARG-OH Chemical Properties |
density | 1.60±0.1 g/cm3(Predicted) | storage temp. | Store at -20°C | solubility | Soluble in DMSO | Sequence | H-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-OH |
| H-ARG-ARG-ARG-ARG-ARG-ARG-ARG-ARG-ARG-OH Usage And Synthesis |
Biological Activity | (Arg)9 (Nona-L-arginine; Peptide R9) is a cell-permeable polypeptide with IC50 value of 0.78 μM for neuroprotection in a glutamate model experimental model. | in vitro | Poly-arginine (eg (Arg)9) and arginine-rich peptides (eg TAT, penetratin), which belong to a class of peptides with cell-penetrating properties are neuroprotective. It provides significant neuroprotection in a dose–response manner following glutamic acid exposure (IC 50 =0.78 μM). Following kainic acid exposure, (Arg)9 is neuroprotective, but less effective than in the glutamic acid model (IC 50 =0.81 μM). (Arg)9 also shows neuroprotection following in vitro ischemia (IC 50 =6 μM). | in vivo | (Arg)9) (D-isoform) is neuroprotective in rat stroke models. (Arg)9) is highly neuroprotective, with efficacy increasing with increasing arginine content, has the capacity to reduce glutamic acid-induced neuronal calcium influx and requires heparan sulfate preotoglycan-mediated endocytosis to induce a neuroprotective effect. (Arg)9) (D-isoform) administered intravenously at a dose of 1000 nmol/kg 30 min after reduces permanent middle cerebral artery occlusion (MCAO) infarct volume . | target | IC50: 0.78 μM (neuroprotection) |
| H-ARG-ARG-ARG-ARG-ARG-ARG-ARG-ARG-ARG-OH Preparation Products And Raw materials |
|